| 注册
首页|期刊导航|时珍国医国药|二至丸含药血清对D-gal诱导HK-2细胞衰老的相关机制研究

二至丸含药血清对D-gal诱导HK-2细胞衰老的相关机制研究

单思 洪伟 王沐晨 严小军 刘红宁

时珍国医国药2025,Vol.36Issue(9):1633-1638,6.
时珍国医国药2025,Vol.36Issue(9):1633-1638,6.DOI:10.70976/j.1008-0805.SZGYGY-2025-0906

二至丸含药血清对D-gal诱导HK-2细胞衰老的相关机制研究

Study on the mechanisms of Er'zhi Pill(二至丸)-containing serum in D-gal-induced cel-lular senescence in HK-2 cells

单思 1洪伟 1王沐晨 1严小军 1刘红宁1

作者信息

  • 1. 江西中医药大学中医基础理论分化发展研究中心,江西省中医病因生物学重点实验室,江西 南昌 330004
  • 折叠

摘要

Abstract

Objective To investigate the effect and underlying mechanism of Er'zhi Pill(二至丸,EZP)-containing serum on D-gal-induced senescence in HK-2 cells.Methods HK-2 cells were randomly divided into five groups:the high/medium/low-concen-tration EZP groups,D-gal-induced senescence model control group,and blank control group.Cell senescence rate was determined u-sing SA-β-gal staining.Flow cytometry(FCM)was used to assess the apoptosis rate and cell membrane permeability.The levels of SOD and MDA were measured by ELISA.The expression levels of AQP1 and AQP2 was detected by Western blot(WB).Results Com-pared with the model control group,the β-gal-positive rate staining in HK-2 cells were decreased in the medium/high-concentra-tion EZP groups(P<0.01).Total apoptosis rate in all EZP groups were reduced in a dose-dependent manner(P<0.01).The high-concentration group showed a significant decrease in MDA(P<0.01)and an increase in SOD activity(P>0.05).Cell membrane permeability was decreased in all EZP groups(P>0.05).AQP1 expression was up-regulated in all EZP groups,while AQP2 expres-sion was increased in the low/high-concentration EZP groups(P>0.05).Conclusion EZP-containing serum exhibits a protective effect against D-gal-induced senescence in HK-2 cells,potentially through the modulation of water metabolism.

关键词

二至丸/衰老/HK-2 细胞/水通道蛋白/细胞膜通透性

Key words

Er'zhi Pill(二至丸,EZP)/Senescence/HK-2 cells/Aquaporin/Cell membrane permeability

分类

医药卫生

引用本文复制引用

单思,洪伟,王沐晨,严小军,刘红宁..二至丸含药血清对D-gal诱导HK-2细胞衰老的相关机制研究[J].时珍国医国药,2025,36(9):1633-1638,6.

基金项目

江西省自然科学基金面上项目(20232BAB206147) (20232BAB206147)

江西中医药大学校级科技创新团队发展计划(CXTD22007) (CXTD22007)

时珍国医国药

OA北大核心

1008-0805

访问量0
|
下载量0
段落导航相关论文